// App-Quantinova.ai

172 : High Content Screening Identifies Synthetic Lethality Of Retinoid Receptor Agonists In IKZF1-Mutated BCR-ABL1 positive Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Michelle Churchman

Principal Investigators

  • Jonathan Low

  • Debbie Payne-Turner

  • Charles G. Mullighan

  • Shann-Ching Chen

  • Jing Ma

  • Mark J. Althoff

  • Faiyaz Notta

  • John E. Dick

  • Laura Janke

  • Rodney Kiplin Guy

  • Taosheng Chen

Medical Centers

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Veterinary Pathology Core, St. Jude Childre-s Research Hospital, Memphis, TN

  • Department of Chemical Biology and Therapeutics, St. Jude Childrens Research Hospital, Memphis, TN

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Cyclin Dependent Kinase Inhibitor 2A

  • Thy-1 Cell Surface Antigen

Drug/Treatment

  • Tretinoin

  • 13-cis retinoic acid

  • carbacyclin

  • Bexarotene

  • dasatinib

  • Tigason

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved